Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Intrinsically disordered proteins (IDPs) lack stable structures, posing challenges for drug targeting.
• The MDM2-p53 interaction regulates cell division; MDM2 inhibits p53 tumor suppression.
• Inhibiting MDM2-p53 binding is a strategy for cancer therapy.

Purpose of the Study:

• To develop novel small molecules targeting the intrinsically disordered N-terminal lid of MDM2.
• To improve binding affinity and drug-like properties of MDM2 inhibitors.
• To evaluate the anti-cancer efficacy of these compounds.

Main Methods:

• Structure-activity relationship (SAR) analysis of small molecule inhibitors.
• Chiral separation and evaluation of key compounds.
• Binding affinity assays (Fluorescence Polarization - FP) and 2D Nuclear Magnetic Resonance (2D NMR).

Main Results:

• A novel 4-point pharmacophore model significantly increased binding affinity (3-fold) compared to previous 3-point models.
• SAR analysis identified key structural features for enhanced binding.
• Several compounds demonstrated specific anti-cancer activity against p53-wild-type cancer cells.

Conclusions:

• The developed small molecules effectively target the MDM2-p53 interaction.
• The 4-point pharmacophore represents a promising advancement in disorder-based drug design.
• These compounds show potential as anti-cancer therapeutics for p53-wild-type cancers.